Financial Performance - Total revenues for the three months ended March 31, 2025, were $27.165 million, an increase of 5.7% compared to $25.718 million for the same period in 2024[19] - Consolidated net income attributable to FONAR for the three months ended March 31, 2025, was $2.506 million, representing a 33.9% increase from $1.872 million in the prior year[19] - Basic net income per common share available to common stockholders increased to $0.38 for the three months ended March 31, 2025, compared to $0.28 for the same period in 2024[19] - Total revenues for the nine months ended March 31, 2025, were $77,075 million, a slight increase from $76,941 million in the same period in 2024, representing a growth of 0.2%[21] - Consolidated net income for the nine months ended March 31, 2025, was $9,329 million, down from $12,463 million, a decrease of 25.5%[21] - Basic net income per common share available to common stockholders was $1.14, compared to $1.42 in the prior year, a decline of 19.7%[21] Assets and Liabilities - Total current assets as of March 31, 2025, were $141.101 million, slightly up from $140.324 million as of June 30, 2024[10] - Total assets increased to $214.923 million as of March 31, 2025, compared to $214.246 million as of June 30, 2024[16] - Total liabilities decreased to $54.664 million as of March 31, 2025, from $57.458 million as of June 30, 2024[13] - The company reported a total equity of $160.259 million as of March 31, 2025, up from $156.788 million as of June 30, 2024[16] Expenses - Total costs and expenses for the nine months ended March 31, 2025, were $66,371 million, up from $61,739 million, indicating an increase of 7.5%[21] - Selling, general, and administrative expenses rose to $20,055 million from $18,046 million, an increase of 11.1%[21] - Research and development expenses for the three months ended March 31, 2025, were $441 thousand, compared to $414 thousand in the same period of 2024[19] - The company reported an interest expense of $21 million, down from $67 million, indicating a decrease of 68.7%[21] Cash Flow - The company had cash and cash equivalents of $54.257 million as of March 31, 2025, compared to $56.341 million as of June 30, 2024[10] - The net cash provided by operating activities for the nine months ended March 31, 2025, was $7,045,000, compared to $9,496,000 in 2024, reflecting a decrease of approximately 25.9%[35] - The company reported a net cash used in investing activities of $3,157,000 for the nine months ended March 31, 2025, compared to $501,000 in 2024[35] Shareholder Information - The weighted average diluted shares outstanding decreased to 6,372 million from 6,538 million[21] - The company repurchased 115 shares at a cost of $1,806 during the nine months ended March 31, 2025, compared to 116 shares at a cost of $1,885 in the same period of 2024[92] - The total net carrying amount of other intangible assets as of March 31, 2025, was $3,230, an increase from $2,870 as of June 30, 2024[80] Revenue Sources - Patient fee revenue decreased to $24,284 million from $25,511 million, reflecting a decline of 4.8% year-over-year[21] - Management and other fees increased to $37,447 million from $36,585 million, showing a growth of 2.4%[21] - Approximately 58.8% of net revenues for the three months ended March 31, 2025, were derived from no-fault and personal injury protection claims, up from 56.3% for the same period in 2024[68] Accounting and Compliance - The company identified three immaterial errors in its financial statements, resulting in an out-of-period charge to expenses of $116,000 for the nine months ended March 31, 2025[53] - The company is evaluating the impact of new accounting standards issued by FASB, which may affect disclosures in future financial statements[54][55] - The company has established a current expected credit loss (CECL) model to address credit risk associated with accounts receivable[60] Taxation - The company recorded an income tax expense of $3,018 for the nine months ended March 31, 2025, down from $4,884 in the same period of 2024, a decrease of 38.2%[96] - The Inflation Reduction Act imposed a 1% excise tax on share repurchases and a 15% corporate alternative minimum tax, but did not have a material impact on the company's financial statements as of March 31, 2025[100] Miscellaneous - The company sold non-controlling interests to a minority shareholder for $132,000 during the nine months ended March 31, 2025[38] - The company recorded $39,000 in investment income from a promissory note during the nine months ended March 31, 2025, with a total sales price of $577,000 for an MRI scanner sold to a related party[105]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-41344 METAL SKY STAR ACQUISITION CORPORATION (Exact name of registrant as specified in its charter) Washington, D.C. 20549 FORM 10-Q Cayman Islands N/A (State or other ...

Financial Performance - As of March 31, 2025, the company reported a net loss of $(153,178) compared to a net income of $297,020 for the same period in 2024[113]. - The company has an accumulated deficit of $7,549,542 and a working capital deficit of $4,671,337 as of March 31, 2025, raising substantial doubt about its ability to continue as a going concern[114]. Initial Public Offering - The company generated gross proceeds of $115,000,000 from the Initial Public Offering of 11,500,000 Units on April 5, 2022[116]. - Following the Initial Public Offering, a total of $115,000,000 was placed in the Trust Account, with transaction costs amounting to $5,704,741[117]. - As of March 31, 2025, the company had investments held in the Trust Account totaling $6,898,161[119]. - The company has no cash held outside of the Trust Account as of March 31, 2025[120]. Debt Obligations - The company issued a promissory note to M-Star Management Corp. for up to $3,000,000, with a balance of $2,972,403 as of March 31, 2025[126]. Business Combination Activities - The company held an Extraordinary General Meeting on October 30, 2023, where shareholders approved extending the deadline for a business combination to August 5, 2024[129]. - As of March 31, 2025, 552,451 public shares remained unredeemed after the redemption of 2,649,965 shares[132]. - The company plans to use funds from the Trust Account to complete its Business Combination and may withdraw interest to pay taxes[119]. - On April 12, 2023, Metal Sky entered into a Merger Agreement with Future Dao Group, valuing Future Dao's outstanding shares at $350 million, resulting in a post-split value of $10.00 per share[134]. - The Merger Agreement was mutually terminated on October 6, 2023, with no fees or expenses required to be paid by either party[135][136]. - On October 1, 2024, Metal Sky signed a non-binding letter of intent for a business combination with Okidoki OÜ, with a total equity value of $120 million[137]. - Metal Sky expressed interest in acquiring Fedilco Group Limited, which holds an 80% equity interest in Viva Armenia, and will seek necessary approvals from Armenian authorities[139]. Risk Management - As of March 31, 2025, the company was not subject to any market or interest rate risk, with net proceeds from its Initial Public Offering invested in U.S. government securities[147].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 001-32146 Commission file number DSS, INC. (Exact name of registrant as specified in its charter) (State or other Jurisdiction of incorporation- or Organization) (IRS Employer Identification No.) 275 Wir ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-16465 Retractable Technologies, Inc. (Exact name of registrant as specified in its charter) Texas 75-2599762 (State or o ...

Clinical Trials and Drug Development - The OnTarget study for crofelemer did not meet its primary endpoint for all tumor types, but showed statistical significance in the subgroup of breast cancer patients, with 183 out of 287 participants being breast cancer patients [323]. - Jaguar is conducting two Phase 2 studies for crofelemer targeting SBS-IF and MVID, with data expected in early 2026 [335]. - Preliminary results from the pediatric IIT of crofelemer in Abu Dhabi were presented at the ELITE PED-GI Congress, indicating ongoing research in rare pediatric diseases [332]. - The company is supporting three proof-of-concept trials and conducting two Phase 2 studies for crofelemer, with the first POC IIT results expected in Q2 2025 [331]. - Jaguar holds global unencumbered rights for crofelemer, Mytesi, and Canalevia-CA1, with several drug product opportunities backed by Phase 2 and POC evidence from human clinical trials [346]. Financial Performance - The company reported a net loss of $10.6 million for the three months ended March 31, 2025, compared to a net loss of $9.4 million for the same period in 2024, reflecting a 13.1% increase in losses [347]. - Total revenue decreased by 5.8% from $2.351 million in Q1 2024 to $2.214 million in Q1 2025, with product revenue declining by 7.7% [372]. - Gross product sales decreased from $3.419 million in Q1 2024 to $3.183 million in Q1 2025, a decline of 6.9% [376]. - License revenue increased to $43,000 in Q1 2025, attributed to a new license agreement with Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret, A.S. [375]. - As of March 31, 2025, the company had total stockholders' equity of $830,000 and an accumulated deficit of $356.9 million [347]. Expenses and Cost Management - Research and development expenses were $3.730 million for Q1 2025, down 13.5% from $4.312 million in Q1 2024 [372]. - Sales and marketing expenses surged by 72.8%, increasing from $1.443 million in Q1 2024 to $2.493 million in Q1 2025 [372]. - General and administrative (G&A) expenses rose by $516,000, or 11.8%, from $4.4 million in 2024 to $4.9 million in 2025, mainly due to higher legal services and personnel costs [385]. - Total cost of product revenue increased by $85,000, or 19.8%, from $430,000 in 2024 to $515,000 in 2025, driven by higher material costs and outsourced contract manufacturing services [378]. - Research and development (R&D) expenses decreased by $582,000, or 13.5%, from $4.3 million in 2024 to $3.7 million in 2025, largely due to reduced clinical and contract manufacturing costs [380]. Cash Flow and Financing Activities - Cash provided by financing activities for the three months ended March 31, 2025, was $4.966 million, a decrease from $12.268 million in 2024, indicating reduced capital inflow [403]. - As of March 31, 2025, the company had cash of $5.7 million, which is insufficient to fund its operating plan for at least one year [392]. - Net cash provided by financing activities for the three months ended March 31, 2025, was $5.0 million, consisting of $3.4 million from Convertible Notes and $1.8 million from shares issued in an At the Market offering [409]. - Net cash provided by financing activities decreased by $7.3 million in 2025, primarily due to a decline in proceeds from the ATM offering, which totaled $11.3 million in the prior period [410]. - For the three months ended March 31, 2025, net cash used in operating activities was $7.3 million, resulting from a net comprehensive loss of $10.9 million [404]. Strategic Partnerships and Collaborations - Jaguar entered into a 5-year exclusive in-license agreement with Venture Life for the commercialization of Gelclair in the US, which was launched in October 2024 [325]. - Jaguar is seeking a partner to fund the expanded development of Canalevia for non-infectious diarrhea in dogs, addressing an estimated six million cases annually in the US [342]. - The joint venture Magdalena focuses on developing plant-based medicines for mental health, with an exclusive license to Jaguar's library of 2,300 medicinal plants [343].

Revenue Performance - Revenues for the three months ended March 31, 2025, were $7,056,116, an increase of $2,178,738 (approximately 44.7%) compared to $4,877,378 for the same period in 2024[138]. - Revenue for Q1 2025 was $7,056,116, up from $4,877,378 in Q1 2024, indicating a significant increase in sales[154]. Cost and Expenses - Cost of revenues for the three months ended March 31, 2025, was $3,131,622, an increase of $1,428,265 (approximately 83.8%) compared to $1,703,357 for the same period in 2024, resulting in a gross profit margin decrease to 56% from 65%[140]. - Research and development expenses increased to $606,237 for the three months ended March 31, 2025, up $216,348 (approximately 55.5%) from $389,889 in 2024, primarily due to the Kyber acquisition[141]. - Sales and marketing expenses rose to $1,382,727 for the three months ended March 31, 2025, an increase of $327,586 (approximately 31%) compared to $1,055,141 in 2024, driven by the Kyber acquisition and higher compensation expenses[142]. - General and administrative expenses slightly decreased to $3,279,094 for the three months ended March 31, 2025, down $4,395 (approximately 0.1%) from $3,283,489 in 2024[143]. Operating Performance - The operating loss for the three months ended March 31, 2025, was $1,394,665, an improvement compared to an operating loss of $1,772,350 for the same period in 2024[138]. - Adjusted EBITDA for Q1 2025 was $(50,778), a decrease of $155,195 compared to $104,417 in Q1 2024, primarily due to higher costs of revenues and operating expenses[155]. - Adjusted EBITDA is used by management as a performance measure, excluding items such as depreciation, stock-based compensation, and interest expenses, to provide a clearer view of operational performance[146]. Cash Flow and Financial Position - Net cash provided by operating activities increased to $448,180 in Q1 2025, a rise of $2,656,250 compared to cash used of $(2,208,070) in Q1 2024[159]. - Net cash provided by investing activities was $838,125 in Q1 2025, an increase of $2,612,550 compared to $(1,774,425) in Q1 2024[160]. - As of March 31, 2025, the company's cash and marketable securities totaled $35,666,432, with outstanding principal and accrued interest on notes amounting to $6,750,326[156]. - The company sold BioTrack for $30,000,000, consisting of $20,000,000 in cash at closing and $10,000,000 in future payments, enhancing liquidity[156]. - Net cash used in financing activities decreased to $172,295 in Q1 2025, down by $859,068 from $(1,031,363) in Q1 2024, primarily due to changes in tax payments[161]. - The company expects to fund future operations and acquisitions through a combination of cash flow, available cash, marketable securities, and debt financing[156]. - The company redeemed $18,881,466 in outstanding principal and interest on its notes during 2024, improving its financial position[156]. Strategic Initiatives - The company acquired all outstanding equity interests of Kyber Data Science, LLC on October 31, 2024, which is expected to enhance its data management capabilities[128]. - The company plans to license data from additional vendors due to a vendor exiting the data licensing business by the end of 2026, which may impact future operations[132]. - The company continues to focus on expanding its marketing and sales efforts to build brand awareness and attract new clients[134]. Accounting and Compliance - The company is currently evaluating the impact of new accounting standards on its consolidated financial statements and disclosures[173].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________to __________ Commission File Number 001-42425 AIFEEX NEXUS ACQUISITION CORPORATION (Exact name of registrant as specified in its charter) Cayman Islands N/A (State or o ...

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________to __________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 Commission File Number 001-42425 AIFEEX NEXUS ACQUISITION CORPORATION (Exact name of registrant as specified in its charter) Cayman Islands N/A (State or o ...

Financial Performance - Revenues for Q1 2025 were $5,879,000, a decrease of 55.4% compared to $13,162,000 in Q1 2024[24]. - Gross profit for Q1 2025 was $1,211,000, down 56.5% from $2,788,000 in Q1 2024[24]. - Net loss for Q1 2025 was $10,186,000, compared to a net loss of $11,003,000 in Q1 2024, representing a 7.4% improvement[24]. - Operating expenses for Q1 2025 totaled $10,480,000, down 19.5% from $13,031,000 in Q1 2024[24]. - The company reported a basic net loss per share of $1.26 for Q1 2025, an improvement from $1.80 in Q1 2024[24]. - Total revenues for the three months ended March 31, 2025, were $5,879,000, a decrease of 55% compared to $13,162,000 for the same period in 2024[69]. - Vehicle sales accounted for $3,600,000 (61% of total revenue) in Q1 2025, down from $11,600,000 (88% of total revenue) in Q1 2024, reflecting a significant decline in deliveries[162]. - The company delivered 22 vehicles in Q1 2025, compared to 60 vehicles in Q1 2024, primarily due to delays in executing sales orders[162]. - The net loss for Q1 2025 was $10.2 million, compared to a net loss of $11.0 million in Q1 2024, reflecting a decrease of $0.8 million or 7%[189]. - Revenues decreased by $7.3 million, or 55%, from $13.2 million in Q1 2024 to $5.9 million in Q1 2025, primarily due to a decrease in unit sales and average selling price[190]. Assets and Liabilities - Total current assets decreased to $73,089,000 as of March 31, 2025, from $82,301,000 as of December 31, 2024, a decline of 11.1%[21]. - Total liabilities decreased to $62,874,000 as of March 31, 2025, from $64,723,000 as of December 31, 2024, a reduction of 2.6%[21]. - Cash and cash equivalents at the end of Q1 2025 were $4,758,000, down from $10,996,000 at the end of Q4 2024, a decrease of 56.7%[21]. - As of March 31, 2025, accounts receivable totaled $22.2 million, net of an allowance of $0.3 million[61]. - Inventory as of March 31, 2025, was $38,006,000, an increase from $36,567,000 as of December 31, 2024[81]. - Other current liabilities increased to $18,878,000 as of March 31, 2025, compared to $17,768,000 as of December 31, 2024[88]. - As of March 31, 2025, total other non-current liabilities amounted to $17.325 million, a decrease from $17.933 million as of December 31, 2024, reflecting a reduction of approximately 3.4%[91]. Cash Flow - The Company reported negative cash flow from operating activities of $4.8 million for the three months ended March 31, 2025, compared to $14.6 million for the same period in 2024[42]. - The net cash used in operating activities was $4.8 million for Q1 2025, compared to $14.6 million for Q1 2024[209]. - Net cash provided by investing activities was $0 for Q1 2025, down from $51.3 million in Q1 2024 due to the acquisition of ElectraMeccanica[213]. - Net cash used in financing activities was $1.5 million for Q1 2025, primarily related to short-term insurance financing and equipment lease principal payments[214]. Acquisitions and Investments - The Company acquired ElectraMeccanica Vehicles Corp. on March 26, 2024, converting each ElectraMeccanica Share into 0.0143739 of a share of the Company's Common Stock, totaling 1,766,388 shares[36]. - As of March 31, 2025, the Company's cash and cash equivalents totaled $4.8 million, reflecting the acquisition of ElectraMeccanica[42]. - The total identifiable assets acquired from ElectraMeccanica amounted to $54,630,000, while total liabilities assumed were $19,042,000, resulting in net assets acquired of $35,588,000[73]. - The acquisition of ElectraMeccanica on March 26, 2024, involved the issuance of 1,766,388 shares of Xos Common Stock, resulting in Xos stockholders owning approximately 79% of the combined entity[72]. Operational Challenges - The Company is experiencing ongoing supply chain disruptions, particularly in power electronics and harnesses, impacting its ability to source inventory[49]. - The Company has significant reliance on single-source suppliers, which poses a risk to its operations and financial condition[62]. - The company is subject to ongoing supply chain disruptions and is actively working with vendors to find alternative solutions[173]. - The company is continuing efforts to find more cost-effective vendors and sources of parts to lower overall production costs[183]. Future Outlook and Strategies - The company is focused on expanding its fleet electrification solutions and charging infrastructure to support electric vehicle fleets[33]. - The company expects future revenue growth to be supported by the increasing demand for e-commerce and last-mile delivery solutions, influenced by regulatory and consumer interest in sustainability[163][164]. - The company plans to raise additional capital through various strategies, including debt financing and equity financing, to support its operations[44]. - The company plans to continue seeking opportunities to reduce costs and cash expenditures to address liquidity and working capital needs[167]. Stock and Equity - The Company issued a convertible promissory note with a principal amount of $20.0 million, maturing on August 11, 2025, bearing an interest rate of 10.0% per annum[97][98]. - The Company entered into a Standby Equity Purchase Agreement allowing it to sell up to $125.0 million of Common Stock until February 11, 2026, with $119.4 million remaining available under the agreement as of March 31, 2025[108][113]. - The Company has a contingent obligation to issue 547,000 shares of Common Stock upon achieving certain market share price milestones, with specific tranches based on the volume-weighted average closing share price[92]. - As of March 31, 2025, the Company had 18,633,301 Public Warrants and 199,997 Private Placement Warrants outstanding, with fair values of $0.2 million and $2,000, respectively[114]. Tax and Compliance - The Company recognized stock-based compensation expense totaling approximately $1.5 million for the three months ended March 31, 2025, compared to $2.0 million for the same period in 2024[132]. - The Company's effective tax rate for the three months ended March 31, 2025, was (0.12)%, lower than the statutory tax rate of 21% due to state taxes and losses not benefited[140]. - The Company reported a net asset position in deferred income taxes at March 31, 2025, primarily due to deferred tax assets from net operating losses[143]. - The company is evaluating the impact of new accounting standards effective after December 15, 2024, which will require additional income tax disclosures[67].